Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Genetic Test Enables Faster Diagnosis of Rare Diseases

By LabMedica International staff writers
Posted on 28 Nov 2025

Rare disease diagnosis often involves a long and uncertain search for the underlying genetic cause. More...

Traditional testing requires multiple separate analyses, although many patients remain without answers. A new clinical solution now offers a faster, more complete way to uncover hereditary conditions: a single test that maps the entire genome more accurately and captures complex variants that older methods miss.

The test, developed and implemented by Radboud University Medical Center (Nijmegen, Netherlands), in collaboration with Maastricht University Medical Center+ (Maastricht, Netherlands), is based on long-read genome sequencing, which measures DNA in much larger fragments and reconstructs all six billion building blocks with significantly higher completeness than short-read approaches. Radboudumc has now begun large-scale clinical use with 5,000 tests per year, initially targeting hereditary blindness and severe intellectual disabilities.

Study findings show that long-read sequencing increases diagnostic yield by more than ten percent for some rare diseases and can detect structural variations that are difficult to identify with conventional methods. The technique also captures DNA modifications that influence gene activity, offering deeper insight into disease mechanisms. Research suggests that ongoing analysis of these full-length genomes could raise the diagnostic uplift to as high as fifteen percent. Published evidence from genomic technology studies supports its suitability and reliability for routine clinical practice.

The introduction of this test is expected to replace around fifteen separate diagnostics, reduce time to diagnosis, and help uncover new hereditary causes of disease. For families, a definitive diagnosis brings clarity, emotional relief, and improved ability to connect with others facing similar conditions. Clinicians can also better assess future reproductive risk and provide more accurate prognostic information. As long-read sequencing becomes a new clinical standard, hospitals anticipate earlier answers and more comprehensive genetic insights for thousands of patients each year.

“Long read sequencing can replace fifteen other genetic tests in clinical practice, making diagnostics faster and more efficient,” said Professor of Genomic Technologies Alexander Hoischen. “I expect this will become the new standard for genome diagnostics and the only test we’ll perform in the future.”

Related Links:
Radboud University Medical Center
Maastricht University Medical Center+ 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.